Genetic And Environmental Risk Factors For Mixed Connective Tissue Disease
Published on: July 31, 2025
Genetic And Environmental Risk Factors For Mixed Connective Tissue Disease
Article author photo

Rand Alanazi

CertHE in Psychology Merit

Article reviewer photo

Sze Yuen Ranee Cheung

BSc Biomedical Science, King’s College London

Introduction

Mixed Connective Tissue Disease (MCTD) is a rare autoimmune disorder where the body’s immune system attacks its own tissues, causing features of several other conditions, such as lupus, scleroderma, and polymyositis.¹ Symptoms can include joint pain, muscle weakness, skin changes, and problems with internal organs.¹ The exact cause of MCTD is not fully understood, but doctors and researchers know that a mix of genetic and environmental factors increases risk.² Most people diagnosed with MCTD are women aged between 20 and 50, though it can occur at any age³

The purpose of this article is to explain what is known about the causes and risk factors for MCTD, so you can better understand what might lead to this disease and how it develops. Both genetics and environmental factors are important in the risk for MCTD. People with a family history of autoimmune diseases are more likely to develop MCTD, and certain changes in immune system genes make the condition more likely.⁴ However, having these genetic risks does not mean someone will definitely get the disease. Environmental exposures such as some viral infections, smoking, and possibly certain chemicals can trigger MCTD in people who are already genetically susceptible.⁵ It is the combination of inherited and environmental factors that leads to the condition.

Genetic factors in MCTD

MCTD is classified as an autoimmune disorder. In autoimmune diseases, the immune system mistakenly targets the body's own tissues.⁶ While the exact cause remains unclear, research has shown that genes involved in regulating the immune response are important in MCTD risk.⁴ One of the strongest genetic associations is with a group of genes called human leukocyte antigen (HLA) genes, specifically the HLA-DR4 and HLA-DR2 genes.⁷ These genes control how the immune system distinguishes between normal cells and harmful invaders.

Studies have shown that people with certain versions of these HLA genes have a higher risk of developing MCTD compared to the general population.⁴ For example, HLA-DR4 is found more frequently in people with MCTD than in those without the disease.⁷ HLA-DR2 has also been linked to an increased risk, particularly in people of European descent.⁷ These findings suggest that certain gene variants make it easier for the immune system to lose control and attack the body’s tissues.

Other genetic risk factors include genes related to immune system signalling and inflammation. Some studies suggest that changes in the STAT4 gene, which affects immune cell activity, may also increase the risk of MCTD.⁸ Genetic studies continue to look for more gene variants that might play a role in MCTD and related autoimmune diseases.

Family History and Other Autoimmune DiseasesDespite these findings, most people with MCTD do not have a clear family history of the disease. It is common for people with MCTD to have relatives with other autoimmune conditions, such as rheumatoid arthritis or lupus, rather than MCTD specifically.⁹,21 This points to a shared genetic risk for a range of autoimmune conditions, rather than just one disease.

Twin studies, where one identical twin develops an autoimmune disease and the other does not, show that genetics accounts for part, but not all, of the risk.²² The rest is due to environmental or random factors. This highlights the importance of both genetics and environment in MCTD.

Environmental factors in MCTD

Genetic risk is only part of the story. Many people with high-risk genes never develop MCTD. Certain environmental conditions are needed to trigger the disease in most cases.¹⁰ The exact triggers are not always known, but some have been studied more than others.

Infections

Infections may play a role in triggering MCTD in people who are already genetically vulnerable. Several studies have looked at viruses, such as Epstein-Barr virus (which causes glandular fever), cytomegalovirus, and parvovirus B19, as possible triggers.¹¹ These viruses can disrupt the immune system and make it more likely to attack the body’s own tissues. However, the evidence is mixed, and not everyone with these infections will go on to develop MCTD.

Smoking

Smoking is a well-known risk factor for many autoimmune diseases, and some studies suggest it may increase the risk of MCTD as well.¹² Chemicals in cigarette smoke can change how immune cells behave, increasing inflammation and the likelihood of autoimmunity. For people with a family history or genetic risk factors, smoking may be enough to trigger the disease.

Exposure to chemicals

Exposure to certain chemicals, such as silica dust or solvents, has also been linked to autoimmune diseases, including MCTD, although the evidence is weaker than for infections and smoking.¹³ People who work in industries where they are exposed to these substances may have a slightly higher risk.

Hormones

Hormonal factors may help explain why MCTD is more common in women. Oestrogen, a hormone that is higher in women of childbearing age, can affect the immune system and may make autoimmunity more likely.¹⁴ However, no direct link between oestrogen and MCTD has been proven.

Stress

Stress, both physical and emotional, is sometimes reported to precede the onset of MCTD symptoms.¹⁵ Severe stress can affect immune function and may make the body more prone to autoimmune responses. While stress alone is unlikely to cause MCTD, it may combine with other risk factors to trigger the disease.

Interaction between genetic and environmental factors

Having genetic risk factors does not mean a person will definitely develop MCTD. Most people with high-risk genes never get the disease. It usually takes an environmental trigger, such as an infection or smoking, to start the autoimmune process in genetically susceptible individuals.¹⁶

This interaction between genes and the environment is supported by research in other autoimmune diseases as well. For example, in lupus, people with certain HLA gene variants are much more likely to develop the disease after certain viral infections.¹⁷ It is likely that a similar mechanism is at work in MCTD.

Researchers are still studying how these genetic and environmental factors interact. It is not always clear why one person develops MCTD after an infection while another person with the same infection and similar genes does not. Other factors, such as the number of risk genes, the strength of environmental exposure, and even chance, may play a role.

Diagnosis of MCTD

The role of autoantibodies

A key feature of MCTD is the presence of a specific antibody in the blood called anti-U1 ribonucleoprotein (anti-U1 RNP) antibody.¹⁸ Autoantibodies are immune proteins that target the body's own tissues. The presence of anti-U1 RNP antibodies is essential for the diagnosis of MCTD, as it is found in almost all people with the disease.

While the exact role of anti-U1 RNP antibodies in causing MCTD is not fully understood, their presence shows that the immune system is reacting against a part of the body’s own cells. Some studies suggest that the genetic risk factors discussed above may make it more likely for the body to make these autoantibodies after exposure to a trigger such as a virus.¹⁹

Other autoantibodies, such as anti-Ro or anti-La, can be found in some people with MCTD, but anti-U1 RNP is the most specific for this disease. The presence of these antibodies helps doctors distinguish MCTD from other autoimmune diseases with similar symptoms.²⁰

Why risk factors matter

Understanding the genetic and environmental risk factors for MCTD can help with earlier diagnosis and better management. Doctors will often ask about family history, environmental exposures, and possible triggers when diagnosing MCTD. Knowing the risks can also help with decisions about lifestyle, such as avoiding smoking or managing stress.

Early diagnosis is important because treatment can slow down or reduce symptoms, protecting organs from damage.²³ There is currently no cure for MCTD, but medications can help control the immune system and manage symptoms. Knowing that someone is at higher risk can prompt earlier testing and treatment if symptoms appear.

Future research

Research continues to look for more genetic markers and environmental triggers for MCTD. The hope is that, in the future, genetic tests may help identify people at risk before symptoms start. Scientists are also working to better understand how environmental exposures trigger disease in genetically susceptible people. These findings may eventually lead to new ways to prevent or treat MCTD.²⁴

FAQs

What is mixed connective tissue disease?

It is an autoimmune disease with features of lupus, scleroderma, and polymyositis.

Is MCTD genetic?

Genes increase the risk, but do not cause the disease on their own.

Can you inherit MCTD from your parents?

You can inherit a higher risk, but not the disease itself.

What environmental factors trigger MCTD?

Infections, smoking, and some chemicals can trigger the disease in susceptible people.

Is there a test for MCTD?

Yes, blood tests for autoantibodies, especially anti-U1 RNP, are used.

Can MCTD be prevented?

There is no sure way to prevent it, but avoiding triggers like smoking may help lower the risk.

Summary

Mixed Connective Tissue Disease is caused by a combination of genetic and environmental factors. Genes involved in the immune system, especially certain HLA types, increase the risk, but environmental triggers such as infections and smoking are usually needed for the disease to start. The presence of specific autoantibodies, like anti-U1 RNP antibodies, is central to diagnosis. While family history can increase risk, MCTD does not typically run directly in families. Understanding these risk factors can help with earlier diagnosis and better management. Ongoing research aims to clarify these links and improve outcomes for people with MCTD.

References

  1. NHS. Mixed connective tissue disease. [Internet]. 2023 [cited 2024 Jun 23]. Available from: https://www.nhs.uk/conditions/mixed-connective-tissue-disease/
  2. Moutsopoulos HM. Mixed connective tissue disease (MCTD): clinical features, diagnosis, and pathogenesis. UpToDate [Internet]. 2023 [cited 2024 Jun 23]. Available from: https://www.uptodate.com/contents/mixed-connective-tissue-disease-clinical-features-diagnosis-and-pathogenesis
  3. Chlebowski RT, Weiner JM, Rosen SW. Mixed connective tissue disease: epidemiology, clinical and immunologic features. Am J Med. 1979;67(5):886-896.
  4. Arnett FC, Sharp GC. Mixed connective tissue disease: definition and management. Baillieres Clin Rheumatol. 1989;3(2):407-436.
  5. Parks CG, Cooper GS, Nylander-French LA, Sanderson WT, Dement JM, Cohen PL, Dooley MA, Treadwell EL, St Clair EW, Gilkeson GS, Savitz DA, Fryzek JP. Occupational exposure to crystalline silica and risk of developing systemic autoimmune diseases. Environ Health Perspect. 1999;107(5):389-394.
  6. Satoh M, Ajmani AK, Ogasawara T, Langdon JJ, Hirakata M, Wang J, Reeves WH. Clinical interpretation of antinuclear antibody tests in systemic rheumatic diseases. Mod Rheumatol. 2008;18(4):354-365.
  7. Genth E, Ungerer T, Duschner H, Mierau R. HLA-DR antigens in mixed connective tissue disease. Arthritis Rheum. 1987;30(1):52-55.
  8. Remmers EF, Plenge RM, Lee AT, Graham RR, Hom G, Behrens TW, de Bakker PI, Le JM, Lee HS, Batliwalla FM, Li W, Masters SL, Booty MG, Carulli JP, Padyukov L, Alfredsson L, Huizinga TW, Toes RE, Begovich AB, Criswell LA, Amos CI, Seldin MF, Kastner DL, Gregersen PK. STAT4 and the risk of rheumatoid arthritis and systemic lupus erythematosus. N Engl J Med. 2007;357(10):977-986.
  9. Cooper GS, Stroehla BC. The epidemiology of autoimmune diseases. Autoimmun Rev. 2003;2(3):119-125.
  10. Kahlenberg JM, Kaplan MJ. Mechanisms of premature atherosclerosis in rheumatoid arthritis and lupus. Annu Rev Med. 2013;64:249-263.
  11. Shoenfeld Y, Agmon-Levin N. 'ASIA' – autoimmune/inflammatory syndrome induced by adjuvants. J Autoimmun. 2011;36(1):4-8.
  12. Costenbader KH, Karlson EW. Cigarette smoking and autoimmune disease: what can we learn from epidemiology? Lupus. 2006;15(11):737-745.
  13. Cooper GS, Parks CG. Occupational and environmental exposures as risk factors for systemic lupus erythematosus. Curr Rheumatol Rep. 2004;6(5):367-374.
  14. Lahita RG. The role of sex hormones in systemic lupus erythematosus. Curr Opin Rheumatol. 1999;11(5):352-356.
  15. Stojanovich L, Marisavljevich D. Stress as a trigger of autoimmune disease. Autoimmun Rev. 2008;7(3):209-213.
  16. Ramos PS, Shedlock AM, Langefeld CD. Genetics of autoimmune diseases: insights from population genetics. J Hum Genet. 2015;60(11):657-664.
  17. Harley JB, James JA. Epstein-Barr virus infection induces lupus autoimmunity. Bull NYU Hosp Jt Dis. 2006;64(1-2):45-50.
  18. Sharp GC, Irvin WS, Tan EM, Gould RG, Holman HR. Mixed connective tissue disease--an apparently distinct rheumatic disease syndrome associated with a specific antibody to an extractable nuclear antigen (ENA). Am J Med. 1972;52(2):148-159.
  19. Mahler M, Kessenbrock K, Szilagyi A, Pruß A, Blüthner M. Clinical and serological follow-up of 21 anti-U1-RNP positive patients. Clin Rheumatol. 2005;24(5):382-388.
  20. Elkayam O, Zandman-Goddard G. Autoantibodies and the diagnosis of mixed connective tissue disease. Isr Med Assoc J. 2013;15(4):204-208.
  21. Vyse TJ, Todd JA. Genetic analysis of autoimmune disease. Cell. 1996;85(3):311-318.
  22. Somers EC, Thomas SL, Smeeth L, Hall AJ. Autoimmune diseases co-occurring within individuals and within families: a systematic review. Epidemiology. 2006;17(2):202-217.
  23. Gunnarsson R, Molberg Ø, Gilboe IM, Gran JT. The prevalence and incidence of mixed connective tissue disease: a national multicentre survey of Norwegian patients. Ann Rheum Dis. 2011;70(6):1047-1051.
  24. Ramos PS, Criswell LA, Moser KL, Comeau ME, Williams AH, Pajewski NM. Potential genetic influences on the development of autoimmune diseases. Curr Opin Rheumatol. 2019;31(6):826-834.
Share

Rand Alanazi

CertHE in Psychology Merit
BSc Biomedical Sciences student - (3rd year)

Rand is a Biomedical Sciences graduate specialising in creating clear and engaging articles on genetics, simplifying intricate scientific concepts to ensure accessibility and clarity, contributing to the development of educational materials that enhance public understanding of genetic disorders and health topics.

arrow-right